Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00441883 · ClinicalTrials.gov registry record · Phase 2
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
A Phase 2 study of Ocular Hypertension and Primary Open Angle Glaucoma, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
- 19
- Study locations
NCT00441883: Completed Phase 2 study of Ocular Hypertension and Primary Open Angle Glaucoma, sponsored by Bausch & Lomb Incorporated.
NCT00441883 is a Phase 2 study of Ocular Hypertension and Primary Open Angle Glaucoma that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 176 participants, below the 275-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (36% lower). The trial reports 19 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00441883, a Phase 2 study of Ocular Hypertension and Primary Open Angle Glaucoma, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
- 19
- Study locations
Study Summary
This study will evaluate the safety and efficacy of PF 03187207.
Primary Outcome
Intraocular pressure (IOP) was measured using a Goldmann applanation tonometer. Diurnal IOP, defined as the mean IOP over the day based on values obtained at 8 AM, 10 AM, 1 PM, and 4 PM, was calculated for each visit. Both eyes were tested, with the right eye preceding the left eye. The operator initially set the dial at 10 mmHg, then looked through the slit lamp and adjusted the dial to take the reading, and then recorded the results. The procedure was repeated on the same eye twice consecutive
Conditions Studied
Interventions
- DRUG PF-03187207 and Latanoprost Vehicle
- DRUG Latanoprost 0.005% and PF-03187207 Vehicle
Study Locations (19)
California
- Pfizer Investigational Site - Artesia
- Pfizer Investigational Site - Newport Beach
- Pfizer Investigational Site - Petaluma
- Pfizer Investigational Site - Poway
Florida
- Pfizer Investigational Site - Jacksonville
- Pfizer Investigational Site - Ormond Beach
Georgia
- Pfizer Investigational Site - Atlanta
- Pfizer Investigational Site - Atlanta
North Carolina
- Pfizer Investigational Site - Charlotte
- Pfizer Investigational Site - High Point
Pennsylvania
- Pfizer Investigational Site - Cranberry Township
- Pfizer Investigational Site - Pittsburgh
Connecticut
- Pfizer Investigational Site - Danbury
Indiana
- Pfizer Investigational Site - Evansville
Kentucky
- Pfizer Investigational Site - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
What the finished NCT00441883 record still lists
NCT00441883 is an interventional study that assigns participants to a tested intervention. The registered 176 participants enrollment target is mid-sized for trials with a published cap, below the 275-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (36% lower).
The record links to 4 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which PF-03187207 and Latanoprost Vehicle is the first listed.
NCT00441883 lists 19 locations in 12 states (California, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT00441883 about?
NCT00441883 is a clinical study titled "Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma". This study will evaluate the safety and efficacy of PF 03187207.
What is the current status of trial NCT00441883?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2007-03. Estimated completion is 2008-07.
What conditions does trial NCT00441883 study?
This clinical trial studies the following conditions: Ocular Hypertension, Primary Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma.
What interventions are being tested in trial NCT00441883?
The interventions under investigation include: PF-03187207 and Latanoprost Vehicle (DRUG), Latanoprost 0.005% and PF-03187207 Vehicle (DRUG).
Who is sponsoring clinical trial NCT00441883?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00441883 being conducted?
This trial has 19 study locations across California, Connecticut, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00441883's enrollment target sits among peer trials
176 25th of 54 higher than 30 of 54 other Ocular Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ocular Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Travoprost Five Day Posology Study
COMPLETED · Phase 2
-
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
COMPLETED · Phase 2
-
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
-
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
COMPLETED · Phase 2
-
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03304821 · 176 participants · Phase 2
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
- NCT03447938 · 176 participants · NA
The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial
- NCT03824145 · 176 participants · NA
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
- NCT04177914 · 176 participants · Phase 3
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia